These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18393001)

  • 41. Current status of isolated limb infusion with mild hyperthermia for melanoma.
    Thompson JF; Kam PC
    Int J Hyperthermia; 2008 May; 24(3):219-25. PubMed ID: 18393000
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
    Brady MS; Brown K; Patel A; Fisher C; Marx W
    Ann Surg Oncol; 2006 Aug; 13(8):1123-9. PubMed ID: 16791448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma.
    Möller MG; Salwa S; Soden DM; O'Sullivan GC
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1611-30. PubMed ID: 19895245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
    Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS
    Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma?
    Garrido-Laguna I; Ponz M; Espinós J
    J Clin Oncol; 2007 Mar; 25(9):1149; author reply 1149-51. PubMed ID: 17369585
    [No Abstract]   [Full Text] [Related]  

  • 47. [Malignant melanoma--diagnosis and treatment].
    Jacobsen KD; Fosså SD; Aamdal S
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3094-7. PubMed ID: 17160112
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Monomelic thermochemotherapy for malignant melanoma of the limbs. Results of a homogeneous series of 128 patients].
    Kretz JG; Grosshans E; Bartier JC; Chartier C; Mantz F; Chafke N
    Chirurgie; 1990; 116(8-9):655-62. PubMed ID: 2129980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The treatment of malignant melanoma.
    Rosin RD
    Eur J Surg Oncol; 1985 Jun; 11(2):111-5. PubMed ID: 3891412
    [No Abstract]   [Full Text] [Related]  

  • 50. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Ann Surg; 2009 Jun; 249(6):1008-13. PubMed ID: 19474677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Cancer; 2009 May; 115(9):1932-40. PubMed ID: 19288571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current clinical and research approaches to optimizing regional chemotherapy: novel strategies generated through a better understanding of drug pharmacokinetics, drug resistance, and the development of clinically relevant animal models.
    Beasley GM; Kahn L; Tyler DS
    Surg Oncol Clin N Am; 2008 Oct; 17(4):731-58, vii-viii. PubMed ID: 18722915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biologic behavior and treatment of intransit metastasis of melanoma.
    Karakousis CP; Choe KJ; Holyoke ED
    Surg Gynecol Obstet; 1980 Jan; 150(1):29-32. PubMed ID: 7350699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. History of regional chemotherapy for cancer of the extremities.
    Ariyan CE; Brady MS
    Int J Hyperthermia; 2008 May; 24(3):185-92. PubMed ID: 18392997
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
    Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
    Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Natural history and selective management of in transit melanoma.
    Wong JH; Cagle LA; Kopald KH; Swisher SG; Morton DL
    J Surg Oncol; 1990 Jul; 44(3):146-50. PubMed ID: 2370798
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Microscopic satellitosis in patients with primary cutaneous melanoma: implications for nodal basin staging.
    Kimsey TF; Cohen T; Patel A; Busam KJ; Brady MS
    Ann Surg Oncol; 2009 May; 16(5):1176-83. PubMed ID: 19224283
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnosis and treatment of in-transit melanoma metastases.
    Testori A; Ribero S; Bataille V
    Eur J Surg Oncol; 2017 Mar; 43(3):544-560. PubMed ID: 27923593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Where are we going with regional therapy for melanoma?
    Tyler D
    Ann Surg Oncol; 2004 May; 11(5):455-7. PubMed ID: 15078631
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.